# Study Exploring the Supportive Effect of Acarbose in Weight Management

> **NCT05934110** · PHASE2 · UNKNOWN · sponsor: **Empros Pharma AB** · enrollment: 320 (estimated)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** EMP16-120/40
- **DRUG:** MR orlistat 120 mg
- **DRUG:** Conventional orlistat 120 mg,
- **DRUG:** EMP16-60/20
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05934110
- **Lead sponsor:** Empros Pharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-04-18
- **Primary completion:** 2023-11-21
- **Final completion:** 2024-03-15
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2024-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05934110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05934110, "Study Exploring the Supportive Effect of Acarbose in Weight Management". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05934110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*